FDA demands trial transparency

The Food and Drug Administration said on April 13 that more than 2,200 companies and researchers appear to be missing required clinical-trial results disclosures. (fda.gov) The agency said those March 30 messages covered more than 3,000 registered trials and asked sponsors to comply voluntarily before regulators consider stronger action. (fda.gov) ClinicalTrials.gov is the federal database where sponsors must post basic trial information and summary results for certain studies of Food and Drug Administration-regulated products. The current rule took effect on January 18, 2017, and compliance has been required since April 18, 2017. (clinicaltrials.gov) For many covered trials, results are due no later than one year after the study’s primary completion date. The law traces back to the Food and Drug Administration Amendments Act of 2007, known as FDAAA 801. (clinicaltrials.gov) The Food and Drug Administration said companies and researchers often fail to disclose negative results, creating publication bias that makes products look more successful than they are. Its internal analysis found 29.6% of studies highly likely to fall under mandatory reporting rules had no results posted. (fda.gov) The missing studies are not a paperwork issue alone. The agency said gaps in the database can distort how doctors, researchers, and patients judge a product’s safety and effectiveness. (fda.gov) The enforcement path is already on the books. The Food and Drug Administration says it can send a pre-notice of noncompliance, give the responsible party 30 days to respond, and then issue a formal notice if the problem is not fixed. (fda.gov) That system is no longer theoretical: the agency’s pre-notice page listed 226 entries as of January 15, 2026, with quarterly posting planned. The page says potential violations include failing to register a trial, failing to submit results, or submitting false or misleading information. (fda.gov) The push reaches beyond drug trials. The National Institutes of Health says the reporting rules are meant to make trial information publicly available in a timely way, and the Food and Drug Administration has separately warned device makers about unreliable third-party testing data used in submissions. (nih.gov) (fda.gov) That puts extra pressure on companies selling diagnostics, software, and artificial-intelligence tools for medicine to show how their products were tested and what the results actually were. The Food and Drug Administration’s April warning was aimed at old trial records, but its message was current: evidence that stays hidden cannot be checked. (fda.gov)